Advertisement

T-Cell Costimulatory Molecules

  • Qiquan Sun
  • Xian Chang LiEmail author
Chapter

Abstract

Transplant tolerance, similar to transplant rejection, is mediated by T cells, and activation of T cells is a prerequisite for both rejection and induction of donor-specific tolerance. Thus, costimulatory molecules play an important role in regulating rejection or acceptance of the allograft. Because of this, T-cell costimulatory molecules have been at the forefront of transplantation research for decades. The initial paradigm was that engagement of costimulatory molecules, in the context of TCR stimulation, promotes activation, clonal expansion, survival and effector differentiation of T cells, and therefore, their absence would have resulted in anergy and/or apoptotic cell death of activated T cells, a situation that favors transplant survival. Earlier studies, mostly using in vitro models, supported this paradigm. In fact, activation of T cells by TCR stimulation in the presence of CD28 costimulatory blockade often resulted in anergy and apoptosis of responding T cells. An implication of this finding is that by blocking costimulatory signals at a critical time of TCR stimulation, the T-cell response might be aborted, and in the setting of transplantation, rejection might be prevented, which may result in long-term allograft survival and possibly tolerance. Indeed, in selected rodent models, blocking CD28 and/or CD154 costimulation can induce prolonged allograft survival, and in some cases, donor-specific tolerance (Sayegh and Turka 1998). These initial findings generated tremendous enthusiasm toward clinical translation in that therapeutic blockade of key costimulatory pathways may be a promising way to the induction of transplant tolerance.

Keywords

Costimulatory Molecule Tolerance Induction Transplant Model Costimulatory Signal Transplant Tolerance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Anderson AC, Anderson DE, Bregoli L, Hastings WD, Kassam N, Lei C, Chandwaskar R, Karman J, Su EW, Hirashima M, Bruce JN, Kane LP, Kuchroo VK, Hafler DA. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science. 2007;318(5853):1141–3.PubMedCrossRefGoogle Scholar
  2. Ariyan C, Salvalaggio P, Fecteau S, Deng S, Rogozinski L, Mandelbrot D, Sharpe A, Sayegh MH, Basadonna GP, Rothstein DM. Cutting Edge: Transplantation Tolerance through Enhanced CTLA-4 Expression. J Immunol. 2003;171(11):5673–7.PubMedCrossRefGoogle Scholar
  3. Bluestone JA. Is CTLA-4 a master switch for peripheral T cell tolerance? J Immunol. 1997;158:1989–93.PubMedGoogle Scholar
  4. Bluestone JA, Liu W, Yabu JM, Laszik ZG, Putnam A, Belingheri M, Gross DM, Townsend RM, Vincenti F. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant. 2008;8:2086–96.PubMedCrossRefPubMedCentralGoogle Scholar
  5. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27:111–22.PubMedCrossRefPubMedCentralGoogle Scholar
  6. Cai G, Anumanthan A, Brown JA, Greenfield EA, Zhu B, Freeman GJ. CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator. Nat Immunol. 2008;9:176–85.PubMedCrossRefGoogle Scholar
  7. Demirci G, Amanullah F, Kewalaramani R, Yagita H, Strom TB, Sayegh MH, Li XC. Critical role of OX40 in CD28 and CD154 independent rejection. J Immunol. 2004;172:1691–8.PubMedCrossRefGoogle Scholar
  8. Dong C, Juedes AE, Temann UA, Shresta S, Allison JP, Ruddle NH, Flavell RA. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature. 2001;409:97–101.PubMedCrossRefGoogle Scholar
  9. Fecteau S, Basadonna GP, Freitas A, Ariyan C, Sayegh MH, Rothstein DM. CTLA-4 up-regulation plays a role in tolerance mediated by CD45. Nat Immunol. 2001;2:58–63.PubMedCrossRefGoogle Scholar
  10. Habicht A, Kewalaramani R, Vu MD, Demirci G, Blazar BR, Sayegh MH, Li XC. Striking dichotomy of PD-L1 and PD-L2 pathways in regulating alloreactive CD4(+) and CD8(+) T cells in vivo. Am J Transplant. 2007;7:2683–92.PubMedCrossRefGoogle Scholar
  11. Harada H, Salama AD, Sho M, Izawa A, Sandner SE, Ito T, Akiba H, Yagita H, Sharpe AH, Freeman GJ, Sayegh MH. The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity. J Clin Invest. 2003;112(2):234–43.PubMedCrossRefPubMedCentralGoogle Scholar
  12. Jacquot S. CD27/CD70 interactions regulate T dependent B cell differentiation. Immunol Rev. 2000;21:23–30.Google Scholar
  13. Khoury SJ, Sayegh MH. The roles of the new negative T cell costimulatory pathways in regulating autoimmunity. Immunity. 2004;20:529–38.PubMedCrossRefGoogle Scholar
  14. Kirk AD, Harlan DM, Armstrong NN, Davis TA, Dong Y, Gray GS, Hong X, Thomas D, Fechner JH, Knechtle SJ. CTLA-4Ig and anti-CD40L prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A. 1997;94:8789–94.PubMedCrossRefPubMedCentralGoogle Scholar
  15. Kuchroo VK, Umetsu DT, DeKruyff RH, Freeman GJ. The TIM gene family: emerging roles in immunity and disease. Nat Rev Immunol. 2003;3:454–62.PubMedCrossRefGoogle Scholar
  16. Kurtz J, Lie A, Griffith M, Eysaman S, Shaffer J, Anosova N, Turka LA, Benichou G, Sykes M. Lack of role for CsA-sensitive or Fas pathways in the tolerization of CD4 T cells via BMT and anti-CD40L. Am J Transplant. 2003;3:804–16.PubMedCrossRefGoogle Scholar
  17. Lechler R, Garden OA, Turka LA. The complementary roles of deletion and regulation in transplantation tolerance. Nat Rev Immunol. 2003;3(2):147–58.PubMedCrossRefGoogle Scholar
  18. Lechler R, Sykes M, Thomson AW, Turka LA. Organ Transplantation-how much of the promise has been realized? Nat Med. 2005;11(6):605–13.PubMedCrossRefGoogle Scholar
  19. Li XC, Strom TB, Turka LA, Wells AD. T cell death and transplantation tolerance. Immunity. 2001;14:407–16.PubMedCrossRefGoogle Scholar
  20. Markees TG, Phillips NE, Gordon EJ, Noelle RJ, Shultz LD, Mordes JP, Greiner DL, Rossini AA. Long term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4+ T cells, IFN-g, and CTLA-4. J Clin Invest. 1998;101:2446–55.PubMedCrossRefPubMedCentralGoogle Scholar
  21. Murphy KM, Nelson CA, Sedý JR. Balancing co-stimulation and inhibition with BTLA and HVEM. Nat Rev Immunol. 2006;6:671–81.PubMedCrossRefGoogle Scholar
  22. Sánchez-Fueyo A, Tian J, Picarella D, Domenig C, Zheng XX, Sabatos CA, Manlongat N, Bender O, Kamradt T, Kuchroo VK, Gutiérrez-Ramos JC, Coyle AJ, Strom TB. Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol. 2003;4:1093–101.PubMedCrossRefGoogle Scholar
  23. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol. 2004;22:531–62.PubMedCrossRefGoogle Scholar
  24. Sayegh MH, Turka LA. The role of T cell costimulatory activation pathways in transplant rejection. N Engl J Med. 1998;338:1813–21.PubMedCrossRefGoogle Scholar
  25. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol. 2002;2:116–26.PubMedCrossRefGoogle Scholar
  26. So T, Lee SW, Croft M. Immune regulation and control of regulatory cells by OX40 and 4-1BB. Cytokine Growth Factor Rev. 2008;19:253–62.PubMedCrossRefPubMedCentralGoogle Scholar
  27. Subudhi SK, Zhou P, Yerian LM, Chin RK, Lo JC, Anders RA, Sun Y, Chen L, Wang Y, Alegre M-L, Fu Y-X. Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection. J Clin Invest. 2004;113(5):694–700.PubMedCrossRefPubMedCentralGoogle Scholar
  28. Sugamura K, Ishii N, Weinberg AD. Therapeutic targeting of the effector T cell costimulatory molecule OX40. Nat Rev Immunol. 2004;4:420–31.PubMedCrossRefGoogle Scholar
  29. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355:1018–28.PubMedCrossRefGoogle Scholar
  30. Tafuri A, Shahinian A, Bladt F, Yoshinaga SK, Jordana M, Wakeham A, Boucher LM, Bouchard D, Chan VS, Duncan G, Odermatt B, Ho A, Itie A, Horan T, Whoriskey JS, Pawson T, Penninger JM, Ohashi PS, Mak TW. ICOS is essential for effective T-helper-cell responses. Nature. 2001;409:105–9.PubMedCrossRefGoogle Scholar
  31. Tang AL, Teijaro JR, Njau MN, Chandran SS, Azimzadeh A, Nadler SG, Rothstein DM, Farber DL. CTLA4 expression is an indicator and regulator of steady-state CD4+FoxP3+ T cell homeostasis. J Immunol. 2008;181(3):1806–13.PubMedCrossRefPubMedCentralGoogle Scholar
  32. Vincenti F, Kirk AD. What's next in the pipeline. Am J Transplant. 2008;8:1972–81.PubMedCrossRefGoogle Scholar
  33. Vu MD, Xiao X, Gao W, Degauque N, Chen M, Kroemer A, Killeen N, Ishii N, Li XC. OX40 costimulation turns off Foxp3+ Tregs. Blood. 2007;110:2501–10.PubMedCrossRefPubMedCentralGoogle Scholar
  34. Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol. 2005;23:23–68.PubMedCrossRefGoogle Scholar
  35. Williams MA, Trambley J, Ha J, Adams AB, Durham MM, Rees P, Cowan SR, Pearson TC, Larsen CP. Genetic characterization of strain differences in the ability to mediate CD40/CD28-Independent rejection of skin allografts. J Immunol. 2000;165(12):6849–57.PubMedCrossRefGoogle Scholar
  36. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, Nomura T, Sakaguchi S. CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008;322:271–5.PubMedCrossRefGoogle Scholar
  37. Wood KJ, Sagaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol. 2003;3(3):199–210.PubMedCrossRefGoogle Scholar
  38. Xu H, Zhang X, Mannon RB, Kirk AD. Platelet-derived or soluble CD154 induces vascularized allograft rejection independent of cell-bound CD154. J Clin Invest. 2006;116:769–74.PubMedCrossRefPubMedCentralGoogle Scholar
  39. Yang J, Popoola J, Khandwala S, Vadivel N, Vanguri V, Yuan X, Dada S, Guleria I, Tian C, Ansari MJ, Shin T, Yagita H, Azuma M, Sayegh MH, Chandraker A. Critical role of donor tissue expression of programmed death ligand-1 in regulating cardiac allograft rejection and vasculopathy. Circulation. 2008;117(5):660–9.PubMedCrossRefGoogle Scholar
  40. Yang Y, Wilson JM. CD40 ligand dependent T cell activation: requirement of B7-CD28 signaling through CD40. Science. 1996;273:1862–4.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2015

Authors and Affiliations

  1. 1.Department of Renal TransplantationThe Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhouPeople’s Republic of China
  2. 2.Transplant Immunology CenterMethodist Hospital, Methodist Hospital Research Institute, Texas Medical CenterHoustonUSA

Personalised recommendations